PHI with Pulmonary alveolar emphysema
How does this condition affect your private health insurance?
Emphysema pulmonal alveolar is a chronic, progressive lung disease characterized by irreversible damage and enlargement of the air sacs (alveoli) and destruction of their walls. This destruction reduces the surface area for gas exchange and leads to a loss of lung elasticity, making exhalation difficult and trapping air. Symptoms, including shortness of breath, chronic cough, and wheezing, worsen over time. Primarily caused by long-term exposure to irritants like cigarette smoke, it can also be linked to genetic factors such as alpha-1 antitrypsin deficiency. Emphysema is a major component of Chronic Obstructive Pulmonary Disease (COPD), leading to significant impairment of respiratory function and quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Gradual onset over months to years; initial noticeable symptoms are continuous.
Duration of Illness (Lifetime)
Chronic, progressive, lifelong disease.
Cost of Treatment (Initial)
Several hundreds to thousands of dollars for initial diagnosis and medication.
Cost of Treatment (Lifetime)
Tens of thousands to hundreds of thousands of dollars, depending on disease progression, need for oxygen therapy, and hospitalizations.
Mortality Rate
High, especially in advanced stages, significantly reducing life expectancy due to respiratory failure or cardiovascular complications.
Risk of Secondary Damages
Very high; includes cor pulmonale (right-sided heart failure), severe respiratory infections, pneumothorax, muscle wasting, and psychological distress like anxiety and depression.
Probability of Full Recovery
Virtually zero; the damage to the alveoli is irreversible.
Underlying Disease Risk
High probability of co-occurring conditions such as chronic bronchitis, lung cancer, cardiovascular diseases, and in some cases, alpha-1 antitrypsin deficiency.